Schulze, Marco H.

[["dc.bibliographiccitation.firstpage","916"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Emerging Infectious Diseases"],["dc.bibliographiccitation.lastpage","919"],["dc.bibliographiccitation.volume","24"],["dc.contributor.author","Janssen, Hauke"],["dc.contributor.author","Janssen, Iryna"],["dc.contributor.author","Cooper, Paul"],["dc.contributor.author","Kainyah, Clemens"],["dc.contributor.author","Pellio, Theresia"],["dc.contributor.author","Quintel, Michael"],["dc.contributor.author","Monnheimer, Mathieu"],["dc.contributor.author","Groß, Uwe"],["dc.contributor.author","Schulze, Marco H."],["dc.date.accessioned","2020-12-10T18:44:07Z"],["dc.date.available","2020-12-10T18:44:07Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.3201/eid2405.171506"],["dc.identifier.eissn","1080-6059"],["dc.identifier.issn","1080-6040"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78338"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Antimicrobial-Resistant Bacteria in Infected Wounds, Ghana, 20141"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","911"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","European Journal of Clinical Microbiology & Infectious Diseases"],["dc.bibliographiccitation.lastpage","915"],["dc.bibliographiccitation.volume","36"],["dc.contributor.author","Grau, Imma"],["dc.contributor.author","Ardanuy, C."],["dc.contributor.author","Schulze, M. H."],["dc.contributor.author","Linares, Josefina"],["dc.contributor.author","Pallares, Roman"],["dc.date.accessioned","2018-11-07T10:24:43Z"],["dc.date.available","2018-11-07T10:24:43Z"],["dc.date.issued","2017"],["dc.description.abstract","Polymicrobial bacteraemia involving Streptococcus pneumoniae and other bacteria (e.g. Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, Haemophilus influenza, viridans streptococci, Salmonella spp.) occurred in 3.4% of our pneumococcal bacteraemia cases. Compared with 308 controls (monomicrobial bacteraemia), the 77 polymicrobial cases included more males (83 vs 62%, p = 0.001), had serious underlying diseases (100 vs 80%, p < 0.001), abdominal infection (18 vs 5%, p < 0.001), nosocomial infection (33 vs 8%, p < 0.001), shock (40 vs 13%, p < 0.001), and higher mortality (52 vs 18%, p < 0.001). Clinicians must be aware that some patients with pneumococcal bacteraemia may have other bacteria in their blood, which would confer higher mortality and may lead to inappropriate or incomplete antibiotic therapy."],["dc.identifier.doi","10.1007/s10096-016-2885-4"],["dc.identifier.isi","000399694500020"],["dc.identifier.pmid","28054228"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42708"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.issn","1435-4373"],["dc.relation.issn","0934-9723"],["dc.title","Polymicrobial pneumococcal bacteraemia: a case-control study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","The Thoracic and Cardiovascular Surgeon"],["dc.contributor.author","Saha, Shekhar"],["dc.contributor.author","Dudakova, Anna"],["dc.contributor.author","Danner, Bernhard C."],["dc.contributor.author","Kutschka, Ingo"],["dc.contributor.author","Schulze, Marco H."],["dc.contributor.author","Niehaus, Heidi"],["dc.date.accessioned","2022-04-01T10:02:45Z"],["dc.date.available","2022-04-01T10:02:45Z"],["dc.date.issued","2022"],["dc.description.abstract","Abstract Objective The rising incidence of infective endocarditis (IE) accompanied by the de-escalation of antibiotic prophylaxis and the complexity of surgical treatment makes IE a daunting foe. We reviewed all patients who underwent cardiac surgery for IE at our institution with a focus on causative organisms and infective foci. Methods A review of 3,952 consecutive patients who underwent cardiac surgery at our institution between January 2013 and December 2017 revealed 160 patients (4%) who were operated for IE. Results The predominantly affected valves were the aortic (30%) and mitral valve (26.9%) as well as a combination of both (8.8%). A total of 28.8% of patients suffered from prosthetic valve endocarditis (PVE). The most frequently identified causative organisms were Staphylococcus (45.7%), Streptococcus (27.5%), and Enterococcus species (16.7%), which was predominantly associated with PVE (p = 0.050). In 13.1% of patients, a causative organism has not been detected. The most frequent infective foci were dental (15%), soft-tissue infections (15%), spondylodiscitis (10%), and infected intravascular implants (8.8%). Relevant predisposing factors were immunosuppression (9.4%) and intravenous drug abuse (4.4%). Septic cerebral infarctions were diagnosed in 28.8% of patients. Postoperative mortality was 22.5%. Conclusions As the bacterial spectrum and the infective foci are still the “old acquaintances,” and with regard to the increasing incidence of IE, current risk–benefit evaluations concerning antibiotic prophylaxis may need to be revisited."],["dc.identifier.doi","10.1055/s-0041-1740540"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/105997"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-530"],["dc.relation.eissn","1439-1902"],["dc.relation.issn","0171-6425"],["dc.title","Bacterial Spectrum and Infective Foci in Patients Operated for Infective Endocarditis: Time to Rethink Strategies?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","60"],["dc.bibliographiccitation.journal","TrAC Trends in Analytical Chemistry"],["dc.bibliographiccitation.lastpage","70"],["dc.bibliographiccitation.volume","76"],["dc.contributor.author","Hoellein, Ludwig"],["dc.contributor.author","Kaale, Eliangiringa"],["dc.contributor.author","Mwalwisi, Yonah H."],["dc.contributor.author","Schulze, M. H."],["dc.contributor.author","Holzgrabe, Ulrike"],["dc.date.accessioned","2018-11-07T10:18:45Z"],["dc.date.available","2018-11-07T10:18:45Z"],["dc.date.issued","2016"],["dc.description.abstract","Counterfeit and substandard medicines still constitute a worldwide problem and do not only affect health-care systems in low and middle income countries but also in the industrialized world. Whereas in the developed world the quality of pharmaceutical preparations is assured by a dense network of quality control laboratories utilizing modern analytical techniques the situation is completely diverse in resource constraint countries. Implementing full monograph testing according to the American or the European Pharmacopoeia represents an extreme challenge. The respective quality control organs easily become overburdened and face central problems when supplying immaculate medicines. This review collected information on the prevalence of counterfeit and substandard pharmaceuticals in Tanzania and discusses suitable analytical approaches for their analysis, e.g. non-sophisticated HPLC, low-field NMR, capillary electrophoresis, or vibrational spectroscopy. Due to the limited validity and reproducibility of field assay kits like the Minilab (R) the impact of precise, simple, and robust analytical methods is highlighted. (C) 2015 Elsevier B.V. All rights reserved."],["dc.identifier.doi","10.1016/j.trac.2015.11.009"],["dc.identifier.isi","000370096800006"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41516"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Sci Ltd"],["dc.relation.issn","1879-3142"],["dc.relation.issn","0165-9936"],["dc.title","Routine quality control of medicines in developing countries: Analytical challenges, regulatory infrastructures and the prevalence of counterfeit medicines in Tanzania"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","157"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Breast Cancer Research and Treatment"],["dc.bibliographiccitation.lastpage","166"],["dc.bibliographiccitation.volume","87"],["dc.contributor.author","Binder, Claudia"],["dc.contributor.author","Simon, Alfred"],["dc.contributor.author","Binder, L."],["dc.contributor.author","Hagemann, T."],["dc.contributor.author","Schulz, M."],["dc.contributor.author","Emons, G."],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Einspanier, Almuth"],["dc.date.accessioned","2018-11-07T10:45:48Z"],["dc.date.available","2018-11-07T10:45:48Z"],["dc.date.issued","2004"],["dc.description.abstract","Relaxin (RLX) is known to induce remodeling of benign stromal tissues through upregulation of matrix metalloproteases (MMPs). Recently, we could show that RLX also induces MMPs in breast cancer cells and enhances in vitro invasiveness. To investigate its potential role for progression of breast cancer in vivo, RLX serum concentrations were determined in 160 breast cancer patients during post-surgical follow-up. RLX concentrations in cancer patients were significantly higher than in a control population of healthy blood donors and patients with various other diseases (0.47 versus 0.29 ng/ml, p < 0.0001). There was a significant difference between patients with metastases (0.62 ng/ml) and those without (0.38 ng/ml, p < 0.0001). Overall survival was shorter in RLX-positive (>0.4 ng/ml) than in RLX-negative patients (p = 0.016). Cox regression analysis showed that RLX was not an independent variable, in contrast to metastatic disease and primary lymph node involvement. Taken together, the detection of elevated RLX concentrations especially in patients with metastases supports the assumption that there is a role for RLX in tissue remodeling during breast cancer progression."],["dc.identifier.doi","10.1023/B:BREA.0000041622.30169.16"],["dc.identifier.isi","000223914900005"],["dc.identifier.pmid","15377840"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/47592"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Kluwer Academic Publ"],["dc.relation.issn","0167-6806"],["dc.title","Elevated concentrations of serum relaxin are associated with metastatic disease in breast cancer patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","144"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Hepatology"],["dc.bibliographiccitation.lastpage","159"],["dc.bibliographiccitation.volume","45"],["dc.contributor.author","Nussler, A."],["dc.contributor.author","Konig, Sarah"],["dc.contributor.author","Ott, M."],["dc.contributor.author","Sokal, E."],["dc.contributor.author","Christ, B."],["dc.contributor.author","Thasler, W."],["dc.contributor.author","Brulport, M."],["dc.contributor.author","Gabelein, G."],["dc.contributor.author","Schormann, W."],["dc.contributor.author","Schulze, M."],["dc.contributor.author","Ellis, E."],["dc.contributor.author","Kraemer, M."],["dc.contributor.author","Nocken, F."],["dc.contributor.author","Fleig, W."],["dc.contributor.author","Manns, M."],["dc.contributor.author","Strom, S. C."],["dc.contributor.author","Hengstler, Jan G."],["dc.date.accessioned","2018-11-07T09:36:53Z"],["dc.date.available","2018-11-07T09:36:53Z"],["dc.date.issued","2006"],["dc.description.abstract","In recent years the interest in liver cell therapy has been increasing continuously, since the demand for whole liver transplantations in human beings far outweighs the supply. From the clinical point of view, transplantation of hepatocytes or hepatocyte-like cells may represent an alternative to orthotopic liver transplants in acute liver failure, for the correction of genetic disorders resulting in metabolically deficient states, and for late stage liver disease such as cirrhosis. Although the concept of cell therapy for various diseases of the liver is widely accepted, the practical approach in humans often remains difficult. An international expert panel critically discussed the recent published data on clinical and experimental hepatocyte transplantation and the possible role of stem cells in liver tissue repair. This paper aims to summarise the present status of cell based therapies for liver diseases and to identify areas of future preclinical and clinical research. (c) 2006 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved."],["dc.identifier.doi","10.1016/j.jhep.2006.04.002"],["dc.identifier.isi","000238782200016"],["dc.identifier.pmid","16730092"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32713"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","0168-8278"],["dc.title","Present status and perspectives of cell-based therapies for liver diseases"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1499"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Journal of Clinical Microbiology"],["dc.bibliographiccitation.lastpage","1500"],["dc.bibliographiccitation.volume","50"],["dc.contributor.author","Tappe, Dennis"],["dc.contributor.author","Schulze, M. H."],["dc.contributor.author","Oesterlein, Anett"],["dc.contributor.author","Abele-Horn, Marianne"],["dc.contributor.author","Baron, Stefan"],["dc.contributor.author","Durchholz, Daniel"],["dc.contributor.author","Langen, Heinz-Jakob"],["dc.contributor.author","Jany, Berthold"],["dc.contributor.author","Schoen, Christoph"],["dc.date.accessioned","2018-11-07T09:11:46Z"],["dc.date.available","2018-11-07T09:11:46Z"],["dc.date.issued","2012"],["dc.description.abstract","Spondylodiscitis caused by Campylobacter species is a rare disease which is most often caused by Campylobacter fetus. We report a case of culture-negative spondylodiscitis and a psoas abscess due to Campylobacter jejuni in a 68-year-old woman, as revealed by 16S rRNA gene and Campylobacter-specific PCRs from biopsied tissue."],["dc.identifier.doi","10.1128/JCM.06275-11"],["dc.identifier.isi","000302148700070"],["dc.identifier.pmid","22259199"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26796"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Microbiology"],["dc.relation.issn","0095-1137"],["dc.title","Molecular Detection of Campylobacter jejuni as a Cause of Culture-Negative Spondylodiscitis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","889"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Journal der Deutschen Dermatologischen Gesellschaft"],["dc.bibliographiccitation.lastpage","893"],["dc.bibliographiccitation.volume","17"],["dc.contributor.author","Kromer, Christian"],["dc.contributor.author","Fabri, Mario"],["dc.contributor.author","Schlapbach, Christoph"],["dc.contributor.author","Schulze, Marco H."],["dc.contributor.author","Groß, Uwe"],["dc.contributor.author","Schön, Michael P."],["dc.contributor.author","Buhl, Timo"],["dc.date.accessioned","2020-12-10T18:27:20Z"],["dc.date.available","2020-12-10T18:27:20Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1111/ddg.13925_g"],["dc.identifier.eissn","1610-0387"],["dc.identifier.issn","1610-0379"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/76313"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Diagnose mykobakterieller Hautinfektionen"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","3300"],["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","Epidemiology and Infection"],["dc.bibliographiccitation.lastpage","3304"],["dc.bibliographiccitation.volume","144"],["dc.contributor.author","Gerhold, G."],["dc.contributor.author","Schulze, M. H."],["dc.contributor.author","Gross, U."],["dc.contributor.author","Bohne, Wolfgang"],["dc.date.accessioned","2020-12-10T15:22:19Z"],["dc.date.available","2020-12-10T15:22:19Z"],["dc.date.issued","2016"],["dc.description.abstract","The increasing prevalence of extended-spectrum beta-lactamase (ESBL)-producing Gram-negative bacteria is a serious threat for current healthcare settings. In this study we investigated the molecular epidemiology of ESBL-producing E. coli at the University Medical Center Gottingen in Lower Saxony, Germany. All E. coli isolates with an ESBL phenotype were collected during a 6-month period in 2014. Multilocus sequence typing and CTX-M characterization were performed on 160 isolates. Of the ESBL-producing isolates 95.6% were CTX-M positive. Compared to recent Germany-wide studies, we found CTX-M-1 to occur in higher frequency than CTX-M-15 (44.4% vs. 34.4%). CTX-M-14 and CTX-M-27 were detected at 9.4% and 5.0%, respectively. The globally dominant sequence type (ST) 131, which is often associated with CTX-M- 15, occurred at a relatively low rate of 24%. Major non-ST131 sequence types were ST101 (5%), ST58 (5%), ST10 (4.4%), ST38 (4.4%), ST410 (3.8%) and ST453 (3.1%). Several of these major sequence types were previously shown to be associated with livestock farming. Together, our study indicates that E. coli lineage distribution in individual healthcare settings can significantly differ from average numbers obtained in nationwide studies."],["dc.identifier.doi","10.1017/S0950268816001412"],["dc.identifier.eissn","1469-4409"],["dc.identifier.isi","000388620000019"],["dc.identifier.issn","0950-2688"],["dc.identifier.pmid","27357252"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/73355"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Cambridge Univ Press"],["dc.relation.issn","1469-4409"],["dc.relation.issn","0950-2688"],["dc.title","Multilocus sequence typing and CTX-M characterization of ESBL-producing E. coli : a prospective single-centre study in Lower Saxony, Germany"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","385"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","LaboratoriumsMedizin"],["dc.bibliographiccitation.lastpage","397"],["dc.bibliographiccitation.volume","40"],["dc.contributor.author","Streit, Frank"],["dc.contributor.author","Perl, Thorsten"],["dc.contributor.author","Schulze, M. H."],["dc.contributor.author","Binder, Lutz"],["dc.date.accessioned","2018-11-07T10:05:11Z"],["dc.date.available","2018-11-07T10:05:11Z"],["dc.date.issued","2016"],["dc.description.abstract","Bacterial infections are potentially life-threatening diseases requiring effective antibiotic treatment right from the outset to achieve a favourable prognosis. Therapeutic success depends on the susceptibility of the bacterial pathogen, determined by the minimum inhibitory concentration (MIC), and the concentration of the antibiotic at the focus of infection, which is influenced by drug metabolism and pharmacokinetic (PK) factors. Beta-lactams are time-dependent antibiotics. Bacterial killing correlates with the duration of the drug concentration above the MIC of the pathogen. Critical illness is associated with major PK changes. This may lead to unexpected drug concentrations and unpredictable dose requirements differing significantly from standard dosages. Emerging dosing strategies are therefore based on PK/pharmacodynamic (PD) principles. Therapeutic drug monitoring (TDM) is increasingly playing a key role in antibiotic treatment optimisation in general and in beta-lactam therapy, in particular, notably in severely ill patients. Furthermore, evidence of the superiority of continuous beta-lactam infusions over shorter administration regimens is growing. Target drug concentrations have to be defined, considering MIC values especially in pathogens with limited susceptibility. For reliable TDM results, correct pre-analytical sample handling is indispensable. Personalised, TDM-guided therapy currently offers the most promising approach to assuring that beta-lactam treatment is effective, especially in critically ill patients."],["dc.identifier.doi","10.1515/labmed-2016-0050"],["dc.identifier.isi","000389670400003"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/38851"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Walter De Gruyter Gmbh"],["dc.relation.issn","1439-0477"],["dc.relation.issn","0342-3026"],["dc.title","Personalised beta-lactam therapy: basic principles and practical approach"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]